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Abstract 
 
Purpose: Despite substantial morbidity and mortality of influenza and pneumococcal 
infections in cancer patients treated with chemotherapy, vaccination against both 
illnesses is infrequent. We evaluated the impact of implementation of clinical 
guidelines on vaccination of chemotherapy patients treated in our institute.  
 
Methods: Prospective audit before (2012) and after (2013–2014) the introduction of 
immunisation guidelines for chemotherapy patients in a UK tertiary cancer centre.    
 
Results: Guideline implementation was associated with a significant increase in the 
rate of pneumococcal vaccination compared to the 2012 baseline (47% vs. 25%, 
P=0.0018), though this was not sustained the following year (34%, P =0.13 vs. 
baseline). Influenza vaccine coverage was high (~70%) throughout. There was a 
marked disparity between patients aged ≤65 and those >65 years in the rate of 
pneumococcal vaccination in both 2013 and 2014 (38% vs. 68% and 17 vs. 53%, 
respectively, both P<0.001), and, to a lesser extent, in the rate of influenza 
vaccination in the same period (64 vs. 82%, P<0.1, and 63% vs. 85%, P=0.009 
respectively). 
 
Conclusions: The implementation of clinical vaccine guidelines was associated with 
a significant increase in pneumococcal vaccination, though continued effort appears 
required to deliver persistent improvement. Initiatives to increase vaccination uptake 
in patients aged ≤65 are merited.  
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Introduction  
 
Cancer patients treated with chemotherapy are at increased risk of developing 
complications from influenza and Streptococcus pneumoniae (pneumococci), with 
mortality approaching 9% in some subgroups [1]. These illnesses may also 
compromise cancer treatment by delaying chemotherapy, and result in substantial 
costs to healthcare providers [2]. Although concerns have been raised regarding the 
efficacy of vaccination in patients with malignant disease, studies demonstrate that 
patients with cancer—including those treated with chemotherapy—remain able to 
respond to vaccination and that influenza immunisation in this group reduces 
mortality [3, 4]. Side-effects of both influenza and pneumococcal vaccines are mild, 
and similar to those experienced by the general population [3, 5-7]. Consequently, 
the UK Department of Health (DH) and the US Center for Disease Control (CDC) 
recommend that in the absence of contraindications, patients planned for cytotoxic 
therapy should be vaccinated against both S.pneumoniae and influenza [8, 9].  
 
In the UK, influenza and pneumococcal vaccines are also recommended for adults in 
clinical risk groups, including (but not limited to) chronic respiratory, cardiac, or 
kidney disease, diabetes, immunosuppression and asplenia, and for all adults aged 
over 65 irrespective of risk factors in the absence of contraindications [8]. The US 
CDC recommends that all adults receive annual influenza vaccination regardless of 
age, and that pneumococcal vaccination is given as a one-off (one or two doses 
depending on vaccine type) to adults under 65 with a wider range of risk factors than 
those used in the UK (also including alcoholism and smoking), and those 65 and over 
irrespective of risk. The pneumococcal vaccine strategy in the US includes both 
PCV13 and PPV23 while in the UK only adults with substantial immunosuppression 
as a risk factor receive PCV13 in addition to PPV23 [9]. 
 
Previous studies have demonstrated that vaccination uptake in cancer patients is 
generally poor [10-16] (Table 1), and initiatives to improve this are therefore 
potentially of substantial clinical benefit. We noted that vaccination advice to patients 
from oncologists in our centre was variable, and frequently inconsistent with UK DH 
recommendations. We performed a prospective audit to examine this, developed 
clinical guidelines with intention of improving vaccination uptake, and repeated the 
audit following their implementation.  
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Materials and Methods 
 
We asked patients attending the Chemotherapy Day Unit in in the Oxford Cancer 
Centre in January 2012 to complete an anonymous questionnaire regarding 
vaccination status and prior advice on immunisation from oncologists / specialist 
nurses (Supplementary data 1). We developed vaccination guidelines, and publicised 
these to hospital practitioners by email and internal presentation, and to local primary 
care physicians by email. The guidelines were implemented in September 2012 and 
included a detailed version on the hospital intranet, a summary poster in clinic rooms, 
and a letter for patients to take to primary care physicians. To assess their impact, 
we repeated the audit in January 2013, and April 2014. We used Fisher’s exact test 
to compare categorical data between audits. All P values were two-sided, and 
significance was accepted at P<0.05. Ethical approval was not required for this 
clinical audit, the protocol for which is provided in the Supplementary information 
accompanying this report (Supplementary data 2). 
 
Results  
 
Patient age, tumour type and influenza / pneumococcal vaccination coverage are 
shown in Table 2. Of 72 patients who completed the questionnaire at baseline, 49 
(68.1%) reported prior influenza vaccination, and 18 (25%) reported previous 
pneumococcal vaccination. 18 (25%) respondents recalled specific discussion with 
their oncologist / specialist nurse regarding immunisation (Table 2). In 2013 following 
guideline implementation there was a significant increase in the frequency of 
pneumococcal vaccination (47.7%, P=0.002), and in the proportion of patients who 
recalled advice regarding immunisation from their oncologist / specialist nurse 
(45.5%, P=0.02), though the rate of influenza vaccination was similar to baseline 
(71.6%, P=0.73) (Table 2). However, in 2014 the increase in pneumococcal 
vaccination and recollection of oncology guidance was more modest and not 
significantly greater than baseline (33.6%, P=0.13; and 36.7%, P=0.14, respectively). 
The rate of influenza vaccination (72.7%) was similar to the two previous years 
(Table 2).  
 
We found a substantial and highly significant disparity in the frequency of 
pneumococcal vaccination between patients ≤65 and those >65 years in both 2013 
(37.5% vs. 67.5%, P=0.0004) and 2014 (17.4% vs. 53.4%, P<0.0001). Though less 
marked, there was also discordance in the rates of influenza vaccination according to 
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age in the same periods (64.0% vs. 81.6%, P=0.09 and 62.9% vs. 84.5%, P=0.009 
respectively). In 2013 and 2014, patients aged <65 years more commonly cited 
chemotherapy as the reason for influenza vaccination than older patients (68.8% vs. 
16.1%, and 56.8% vs. 14.3%, respectively; P<0.0001 for both comparisons). Similar 
discordance between age groups was evident in the proportion that reported that 
pneumococcal vaccination was given due to planned systemic anti-cancer therapy 
(40.0% vs. 18.5%, P=0.16 and 75.0% vs. 16.1%, P=0.0005 respectively). 
Unfortunately, lack of collection of data on patient age in the 2012 audit precluded 
comparison of guideline impact between age strata.  
 
 
Discussion 
We have shown that implementation of a vaccination guideline in our centre was 
associated with a significant improvement in the rate of pneumococcal immunisation, 
and an apparent increase in the proportion of physicians/specialist nurses offering 
advice on vaccination. However, the intervention was not associated with an increase 
in the rate of influenza vaccination from a high baseline. The improvement in 
pneumococcal vaccination and proportion recalling vaccination advice was less 
marked two seasons following guideline introduction, suggesting that continued 
emphasis may be required to maintain physician / specialist nurse awareness.  
 
The low coverage of pneumococcal vaccination at baseline in our study (25%), is 
comparable to that previously reported (4-16%) [10-16] (Table 1). Similarly, the rate 
of influenza immunisation in 2011/12 is consistent with the UK national average of 
74% achieved in ‘high risk’ patients (>65 or ‘at risk’) in those years [17], and higher 
than most previous reports (Table 1), due at least in part to the excellent coverage in 
patients aged >65. The failure of our intervention to increase uptake from this high 
baseline is likely to reflect the challenge of improving on what is an already an 
effective primary care-based vaccination strategy in the UK. An important finding of 
our study is the poor vaccination coverage in patients aged 65 or under in contrast to 
high coverage in those aged over 65 where these vaccines form part of a universal 
national programme. This is concordant with previous reports [11, 14, 15], and may 
result from less effective invitation of patients for targeted immunisation by primary 
care physicians than the more systematic invitation of patents that occurs after their 
65th birthday. Improving awareness of the importance of vaccination of such patients 
among general practitioners is likely to be as important as educating hospital 
practitioners in reducing this disparity. 
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Our study has limitations. The use of questionnaires to obtain vaccination histories 
relies on patient recollection, with its attendant risk of bias. However we note that for 
each year in our series all patients recalled their history of influenza vaccination, 
while >80% were able to recall pneumococcal immunisation status. Another limitation 
is the absence of data regarding patient age at baseline, which meant we were 
unable to examine the effect of our guidelines on patients stratified by age. As our 
results highlight that age ≤65 is strongly associated with lack of influenza and 
pneumococcal vaccination in cancer patients, it is important that further studies focus 
on the effect of vaccination initiatives in this patient cohort.  
 
While cancer patients treated with chemotherapy may be less likely to benefit from 
influenza and pneumococcal vaccination than the healthy population (in whom the 
protection is estimated at 50-80%[18], and ~ 50% [19] respectively), the available 
evidence suggests that the proportion of patients who mount an adequate serological 
response is sufficient to justify immunisation. While this is reflected in current DH and 
CDC recommendation [8,9], as noted previously vaccination coverage in this patient 
group is unsatisfactory [10-13]. While demonstrating that implementation of 
immunization guidelines may help to improve coverage, our study highlights that 
there remains scope for improvement, particularly in the ≤65 group.  
 
Conclusions 
In our study, a simple intervention of guidelines, clinician education and a letter for 
general practitioners was associated with a significant improvement in pneumococcal 
vaccination coverage in chemotherapy patients. However, the increase was no 
longer significant two years after baseline, suggesting that continued emphasis on 
the importance of vaccination is required to deliver sustained improvement. 
Vaccination of patients aged ≤65, who are not routinely invited for immunisation by 
general practitioners, is poor – particular effort appears merited to improve uptake in 
this population.  
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 Table 1. Uptake of influenza and pneumococcal vaccination in cancer 
patients 
 
 
 
 
  
 Patient cohort n Date Country 
Rate of 
vaccination Reference 
Influenza 
vaccination 
Solid tumours 110 2003 UK 36% Ring et al [12] 
 Solid tumours 1225 2003 USA 26.7% in 1993 - 
43% in 1998 
Earle et al [13] 
 Solid tumours 112 2008 France 30% Loulergue et al [11] 
 Haematological malignancies 200 2010 France 25.5% Lachenal et al [16] 
 Solid tumours and 
haematological malignancies 
100 2011 Iran 9% Meidani et al [10] 
  129 2011 Canada 57.0% Chin-Yee et al [15] 
 Solid tumours l  359 2013 Turkey 17% Urun et al [14] 
Pneumococcal 
vaccination 
Solid tumours  359 2013 Turkey 4.2% Urun et al [14] 
 
 Solid tumours  96 2014 Sweden 15.6% Berglund et al [23] 
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Table 2. Frequency of influenza and pneumococcal vaccination in chemotherapy 
patients prior and subsequent to guideline implementation  
 
 Jan 2012 
(n=72) 
Jan 2013  
(n=88) 
April 2014 
(n=128) 
P 
 n % n % n % 
2013 vs. 
baseline 
2014 vs. 
baseline 
Age         
Median 
 (range) 
– 
63.5  
(21-83) 
62.0 
(21-103) 
– – 
<65 – – 50 56.8 70 54.7 – – 
>65 – – 38 43.2 58 45.3 – – 
         
Influenza vaccination* 
Yes 49 68.1 63 71.6 93 72.7 0.73 0.52 
No 23 31.9 25 28.4 35 27.3   
Unsure 0 0 0 0 0 0   
         
Pneumococcal vaccination** 
Yes 18 25.0 42 47.7 43 33.6 0.002 0.13 
No 43 59.7 32 36.4 59 46.1   
Unsure 11 15.3 13 14.8 26 20.3   
         
Received vaccination advice*** 
Yes 18 25.0 40 45.5 47 36.7 0.02 0.14 
No 45 62.5 41 46.6 70 54.7   
Unsure 8 11.1 7 8.0 9 7.0   
 
Cancer types by audit period: 
– 2012: breast 16.7%; colorectal 15.3%; gynaecological 16.7%; lung 9.7%; urological 8.3%; other 30.6%; unknown 
2.8%,  
– 2013: breast 6.8%; colorectal 15.9%; gynaecological 8.0%; lung 13.6%; urological 8.0%; haematological 34.1%, 
other 11.4%, unknown 2.3%. 
– 2014: breast 16.4%; colorectal 14.8%; gynaecological 11.7%; lung  6.3%; urological 7.0%; haematological 15.6%; 
other 27.3%; unknown 0.8%.   
* influenza vaccination during current influenza season. **any prior pneumococcal vaccination. *** received 
vaccination advice from treating oncologist / specialist nurse prior to chemotherapy. – Data not available.  
 
 
 
